Pulmonary Hypertension Brands

United Therapeutics' inhaled treprostinil solution (prostacyclin analog), FDA approved July 30, 2009, for pulmonary arterial hypertension (PAH, WHO Group 1), with a second FDA approval in April 2021 for pulmonary hypertension associated with interstitial lung disease (PH-ILD, WHO Group 3), and a dry powder inhaler formulation (Tyvaso DPI) approved in May 2022.